Juno Bio secures $3.8M and opens first sequencing lab dedicated to women's health
Juno Bio, a UK-founded women's health company dedicated to closing the gender health gap through precision vaginal microbiome testing and multi-omics, today announced the opening of its first sequenci... The company is scaling its precision vaginal microbiome platform to provide clinicians and patients with more detailed, clinically actionable insights into infections, fertility and menopausal health. Healthtech Juno Bio secures $3.
Key Takeaways
- 8M and opens first sequencing lab dedicated to women's health The company is scaling its precision vaginal microbiome platform to provide clinicians and patients with more detailed, clinically actionable insights into infections, fertility and menopausal health.
- To fuel this stage of growth, Juno Bio has raised $3.
Investors include Ada Ventures , Artesian , Entrepreneur First, and Illumina Accelerator, investors known for backing early-stage startups spanning women's health, deep tech and applied sequencing.
- Juno Bio's new clinically actionable vaginal microbiome and STI test is designed to address a critical gap in women's health, where recurrent infections, fertility concerns, and peri- and menopausal symptoms are frequently misunderstood or inadequately treated.
Processed in Juno Bio's own CLIA-certified lab, the test analyses approximately 10,000 bacteria and fungi, along with four common STIs, to give patients and clinicians a detailed picture of the vaginal ecosystem.
- "While the field is still evolving, advances in sequencing and data interpretation are moving us closer to a future where more personalised, microbiome-informed care can complement existing diagnostic approaches.
" "Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women's health," said Hana Janebdar, Founder and CEO of Juno Bio.
- We're incredibly grateful to our investors and partners for their trust in our team and our vision as we move into this next stage of growth.
Stats & Key Facts
- #To fuel this stage of growth, Juno Bio has raised $3.
The company is scaling its precision vaginal microbiome platform to provide clinicians and patients with more detailed, clinically actionable insights into infections, fertility and menopausal health. Healthtech Juno Bio secures $3. 8M and opens first sequencing lab dedicated to women's health The company is scaling its precision vaginal microbiome platform to provide clinicians and patients with more detailed, clinically actionable insights into infections, fertility and menopausal health.
Cate Lawrence 1 hour ago Share Share Send email Copy link Juno Bio , a UK-founded women's health company dedicated to closing the gender health gap through precision vaginal microbiome testing and multi-omics, today announced the opening of its first sequencing lab built entirely for women's health. The new facility, in Oakland, California, marks a major step forward in expanding access to high-quality, clinically relevant microbiome testing. To fuel this stage of growth, Juno Bio has raised $3.
Investors include Ada Ventures , Artesian , Entrepreneur First, and Illumina Accelerator, investors known for backing early-stage startups spanning women's health, deep tech and applied sequencing. Using next-generation sequencing, Juno Bio's platform delivers a detailed, clinically actionable view of vaginal health, equipping patients and healthcare providers with deeper insights into conditions that are often misunderstood or misdiagnosed. Since its founding, Juno Bio has pioneered a new standard of care for vaginal microbiome health, building one of the largest repositories of vaginal microbiome data and helping thousands of women access more precise testing and treatment.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation